viral
diseas
affect
hundr
million
peopl
worldwid
avail
drug
treat
diseas
often
come
limit
key
obstacl
develop
new
antivir
agent
deliveri
infect
cell
vi
vo
cellpenetr
peptid
cpp
short
peptid
cross
cellular
lipid
bilay
remark
capabl
shuttl
conjug
cargo
cell
cpp
success
util
enhanc
cellular
uptak
intracellular
traffick
antivir
molecul
therebi
increas
inhibitori
activ
potenti
antivir
protein
oligonucleotid
analogu
cultur
cell
anim
model
review
address
notabl
find
studi
highlight
promis
result
discuss
challeng
cpp
technolog
overcom
clinic
applic
viral
diseas
affect
hundr
million
peopl
worldwid
result
devast
toll
human
health
socioeconom
develop
along
emerg
newlyrecogn
human
pathogen
sar
coronaviru
recent
influenza
virus
everincreas
incid
chronic
viral
infect
caus
hiv
hepat
b
c
virus
continu
increas
open
access
global
burden
infecti
diseas
vaccin
develop
import
viral
pathogen
although
vaccin
hiv
hepat
c
viru
clinic
phase
iii
ii
respect
still
littl
prospect
effect
vaccin
agent
enorm
challeng
develop
vaccin
especi
sinc
million
peopl
alreadi
chronic
infect
virus
would
requir
therapeut
vaccin
control
challeng
emphas
import
chemotherapi
treat
viral
infect
around
antivir
compound
clinic
use
target
variou
viral
diseas
half
drug
use
treatment
patient
hiv
infect
treatment
acut
infect
one
caus
sever
ill
includ
hemorrhag
fever
enceph
even
cancer
avail
drug
limit
efficaci
come
sever
side
effect
importantli
antivir
chemotherapi
plagu
rapid
develop
drug
resist
strain
result
high
rate
replic
virus
combin
low
fidel
replic
genom
view
modest
exist
drug
arsen
continu
threat
pose
viral
pathogen
urgent
call
develop
novel
antivir
agent
oblig
intracellular
parasit
virus
present
formid
challeng
drug
develop
biggest
vivo
deliveri
antivir
drug
infect
cell
minimum
toxic
host
cell
tradit
antivir
therapi
reli
small
molecul
proteas
inhibitor
nucleotid
analogu
inhibit
viral
enzym
last
decad
protein
nucleic
acid
molecul
shown
promis
antivir
properti
howev
due
physic
properti
size
hydrophil
cellular
uptak
molecul
strongli
restrict
inabl
molecul
cross
cell
membran
reach
intracellular
target
preclud
clinic
applic
cellular
deliveri
molecul
thu
arisen
cornerston
therapeut
develop
current
techniqu
cellular
deliveri
antivir
includ
target
liposom
cell
cultur
mice
receptormedi
endocytosi
antibodi
bind
cell
cultur
mice
retrovir
vector
cell
cultur
well
adenovirus
vaccin
deliveri
howev
techniqu
present
certain
limit
concern
low
effici
immunogen
stabil
rapid
clearanc
bloodstream
liposom
reagent
immunogen
viral
integr
host
gene
express
viral
vector
novel
strategi
effici
overcom
imperm
cell
barrier
came
surpris
find
late
certain
natur
occur
short
peptid
sequenc
abil
enter
cell
ad
cultur
media
tat
peptid
deriv
transcript
activ
protein
tat
penetratin
deriv
drosophila
antennapedia
antp
transcript
protein
first
cellpenetr
peptid
cpp
describ
tat
penetratin
pave
way
discoveri
natur
occur
cpp
herpesviru
tegument
protein
cell
wall
proteinderiv
peptid
mycobacterium
tuberculosi
chimaer
cpp
transportan
chimera
neuropeptid
galanin
wasp
venom
toxin
mastoparan
total
synthet
cpp
model
amphipath
peptid
map
arginin
oligom
also
design
routin
use
exact
mechan
cellular
uptak
clear
studi
remain
controversi
current
model
includ
uptak
transient
pore
format
caveola
clathrindepend
endocytosi
macropinocytosi
recent
data
suggest
endocytosi
prevail
model
uptak
although
sever
mechan
may
coexist
differ
depend
cpp
make
peptid
attract
deliveri
system
abil
promot
intracellular
uptak
conjug
cargo
cpp
success
improv
cellular
uptak
variou
cargo
includ
protein
nucleic
acid
oligonucleotid
peptidenucl
acid
sirna
nanoparticul
liposom
wide
rang
cell
mainli
mammalian
cell
also
bacteria
yeast
protozoan
parasit
cpp
proven
effici
deliv
molecul
cell
refractori
transfect
primari
lymphocyt
schwarz
et
l
success
deliv
tissu
mice
tatconjug
protein
retain
enzymat
activ
impress
conjug
also
cross
bloodbrain
barrier
reach
brain
tissu
usual
restrict
small
highli
lipophil
peptid
cpp
offer
opportun
deliv
therapeut
molecul
time
larger
current
bioavail
size
restrict
cppmediat
deliveri
bioactiv
compound
model
organ
cancer
cardiomyopathi
stroke
muscular
dystrophi
viral
infect
support
strong
therapeut
potenti
exert
cpp
clinic
trial
take
cppbase
drug
step
closer
therapeut
applic
heptam
arginineconjug
cyclosporin
psorban
enter
phase
ii
clinic
trial
topic
treatment
psoriasi
oligoarginin
peptid
allow
penetr
cyclosporin
cell
throughout
otherwis
imperm
epidermi
dermi
review
focu
studi
explor
use
cpp
deliv
antisens
agent
virusinfect
cell
anim
model
tabl
past
decad
wit
breakthrough
genesilenc
antisens
agent
includ
antisens
oligonucleotid
ao
ao
analogu
ribozym
dnazym
popular
sirna
novel
approach
base
discoveri
year
ago
nucleic
acid
molecul
could
use
specif
target
complementari
viral
nucleic
acid
sequenc
inhibit
viral
replic
new
promis
molecul
come
abil
simultan
target
multipl
viral
sequenc
would
preclud
select
drug
resist
mechan
antivir
activ
exert
cpp
conjug
antivir
agent
target
retrovirus
shown
hiv
nonretrovir
rna
virus
shown
negativesens
rna
ebov
hcv
dna
virus
shown
hsv
interfer
viral
rna
process
translat
inhibit
viral
replic
cpp
conjug
also
design
target
virusinfect
cell
cpp
also
inactiv
virion
render
cell
resist
infect
inhibit
cell
infect
stand
procaspas
rt
stand
revers
transcript
tn
stand
transportan
far
conjug
cpp
phosphorodiamid
morpholino
oligom
pmo
clearli
popular
promis
use
cpp
antivir
develop
pmo
antisens
dna
oligonucleotid
analogu
backbon
compos
morpholin
ring
join
uncharg
phosphodiamid
linkag
place
sugar
anion
phosphodiest
linkag
dna
typic
synthes
long
oligom
offer
great
featur
clinic
applic
watersolubl
nucleaseresist
uncharg
backbon
interact
weakli
serum
cellular
protein
therebi
reduc
toxic
pmo
mainli
design
interact
noncod
region
target
mrna
augcodon
translat
startsit
region
splice
junction
pmo
effici
enter
cell
investig
routin
arm
cpp
promot
uptak
virusinfect
cell
enhanc
antisens
efficaci
peptideconjug
pmo
refer
ppmo
literatur
highlight
moulton
jiang
pmo
particularli
wellsuit
cargo
cpp
uncharg
compon
interact
positivelycharg
carrier
peptid
therebi
interf
membran
bind
properti
first
report
ppmo
antivir
activ
fuel
increas
interest
pmotechnolog
inhibit
viral
infect
wit
vit
ro
andor
vi
vo
studi
publish
antivir
ppmo
within
last
five
year
tabl
studi
rna
virus
extens
review
stein
latest
vivo
work
discuss
moulton
jiang
focu
overal
find
regard
cell
penetr
moieti
conjug
review
studi
target
dna
virus
peptidemedi
pmo
deliveri
focu
intens
effort
identifi
activ
stabl
non
toxic
endosomolyt
cpp
rxr
xb
also
call
r
larginin
x
acid
b
proven
success
antivir
studi
pmo
coval
link
variou
argininerich
peptid
frequent
r
f
c
r
larginin
f
lphenylalanin
c
lcystein
r
f
r
c
also
call
rxr
xb
conjug
mainli
end
pmo
studi
compar
activ
variou
cpp
murin
hepat
viru
mhv
ebola
viru
ebov
argininerich
peptid
insert
acid
stood
vi
vo
effect
higher
number
repeat
higher
pmo
antivir
effect
mhv
cell
cultur
protect
ebov
infect
mice
find
agre
result
amantana
et
l
abe
et
al
youngblood
et
al
also
found
residu
increas
serum
stabil
enhanc
endosom
escap
conjug
burrer
et
al
document
natur
linker
xb
cystein
affect
ppmo
v
itro
effect
mhv
cytotox
although
insert
residu
report
improv
serum
intracellular
stabil
ppmo
conjug
ppmo
antivir
activ
mainli
exploit
wide
rang
nonretrovir
rna
virus
cell
cultur
ppmo
test
west
nile
viru
wnv
japanes
enceph
viru
st
loui
enceph
viru
dengu
viru
denv
sever
acut
respiratori
syndrom
coronaviru
sarscov
mhv
equin
arter
viru
porcin
reproduct
respiratori
syndrom
viru
footandmouth
diseas
viru
polioviru
human
rhinoviru
coxsackieviru
coxsackieviru
sindbi
viru
venezuelan
equin
enceph
viru
veev
ebov
respiratori
syncyti
viru
rsv
measl
viru
influenza
viru
fluav
cell
cultur
assay
consist
show
ppmo
readili
enter
infect
cell
could
specif
strongli
inhibit
viral
replic
fluoresceinlabel
ppmo
accumul
nucleu
present
throughout
cell
lai
et
al
report
punctuat
foci
signal
cell
cytoplasm
might
indic
endosom
entrap
ppmo
mani
investig
identifi
potent
ppmo
activ
cell
cultur
assay
went
test
antivir
properti
murin
experiment
model
investig
explor
prophylact
therapeut
potenti
ppmo
best
protect
usual
achiev
preinfect
postinfect
ppmo
treatment
ppmo
shown
suppress
viral
replic
attenu
symptom
diseas
andor
increas
survivorship
mice
infect
wnv
denv
mhv
veev
ebov
rsv
fluav
ppmo
demonstr
profound
impress
antivir
effect
particular
two
preinfect
dose
rx
bconjug
pmo
complet
protect
mice
lethal
challeng
ebov
mice
treat
dose
rxr
xbconjug
ppmo
given
preand
postinfect
surviv
veev
lethal
infect
author
found
period
monitor
veev
undetect
ppmotreat
mice
brain
blood
peripher
tissu
ppmo
routin
test
rna
virus
hand
studi
document
use
ppmo
technolog
dna
virus
first
report
came
zhang
et
l
interest
block
kaposi
sarcomaassoci
herpesviru
kshv
lytic
replic
explor
effect
inhibit
express
kshv
latencyassoci
nuclear
antigen
lana
replic
transcript
activ
rta
two
factor
involv
latenc
mainten
switch
lytic
phase
respect
investig
design
pmo
direct
lana
rta
coval
conjug
termin
r
f
r
c
peptid
fluorescein
fl
label
pmo
enter
cell
poorli
flppmo
effici
taken
lymphocyt
emphas
author
difficult
effici
transfect
common
techniqu
lipofectamin
ppmo
could
effect
inhibit
rta
lana
protein
express
cell
cultur
treatment
kshvinfect
cell
rta
ppmo
suppress
kshv
lytic
replic
rta
knock
result
reduc
level
protein
express
downstream
rta
one
downstream
protein
viral
thought
essenti
develop
ksvhassoci
diseas
subsequ
studi
zhang
et
al
block
express
ppmo
pmo
coval
conjug
rxr
xb
r
f
r
c
ppmo
treatment
inhibit
express
turn
reduc
human
level
kshv
yield
reduc
growth
treat
cell
moerdykschauweck
et
al
tackl
reactiv
anoth
dna
viru
herp
simplex
viru
type
investig
antivir
activ
five
rxr
xbconjug
pmo
direct
three
immediateearli
gene
crucial
replic
potent
ppmo
design
strongli
inhibit
replic
cell
cultur
reduc
viral
protein
express
figur
particular
ppmo
abl
suppress
replic
sever
strain
includ
acyclovirresist
strain
author
also
test
ppmo
mous
model
ocular
herp
infect
topic
applic
ppmo
eye
infect
mice
inhibit
viru
replic
mous
eye
reduc
incid
eye
diseas
therebi
prevent
death
associ
eye
infect
evalu
vivo
ppmo
toxic
investig
appli
ppmo
ten
time
antivir
dose
daili
eye
uninfect
mice
gross
microscop
eye
damag
effect
bodi
weight
temperatur
chang
behavior
observ
follow
sevenday
treatment
result
strengthen
potenti
ppmo
treatment
recur
corneal
diseas
reactiv
besid
improv
pmo
cellular
uptak
cpp
moieti
also
shown
intensifi
pmo
antisens
activ
ebov
cellfre
translat
assay
result
consist
find
nelson
et
l
show
ppmo
exhibit
antisens
activ
higher
correspond
pmo
bear
lower
offtarget
effect
author
propos
argininerich
peptid
enhanc
rnapmo
bind
affin
therebi
increas
specif
antisens
activ
ppmo
appear
gener
well
toler
cultur
cell
anim
recipi
howev
studi
report
toxic
cell
cultur
increas
ppmo
dose
longer
period
exposur
vivo
toxic
treatment
dose
increas
usual
dose
higher
antivir
one
peptid
moieti
ppmo
seem
contribut
toxic
dea
et
al
test
pmo
ppmo
wnv
mice
found
mice
could
toler
higher
dose
pmo
compar
ppmo
mg
respect
mice
treat
high
dose
ppmo
would
suffer
weight
loss
develop
abnorm
behavior
smaller
liver
besid
dosedepend
toxic
schedul
treatment
regimen
may
also
affect
ppmo
toxic
burrer
et
al
document
treatmentassoci
toxic
ppmo
administ
healthi
mice
observ
signific
toxic
ppmo
treatment
given
mhv
challeng
lupfer
et
l
report
abnorm
infiltr
mous
lung
immun
system
cell
ppmo
target
fluav
administ
higher
dose
author
hypothes
argininerich
cpp
mimic
eosinophil
major
basic
protein
also
rich
arginin
residu
trigger
migrat
inflammatori
cell
report
pmomedi
antivir
activ
anim
model
pmo
could
success
suppress
viral
replic
vivo
without
help
cpp
understood
warfield
et
al
report
nearli
complet
protect
rhesu
macaqu
ebov
lethal
infect
use
pmo
pmo
also
report
increas
surviv
calicivirusinfect
cat
studi
done
directli
compar
pmo
ppmo
antivir
activ
vivo
one
studi
found
ppmoand
pmotreat
mice
surviv
ebov
lethal
challeng
respect
differ
statist
signific
howev
compar
report
clearli
document
ppmo
far
effect
pmo
mice
ppmo
offer
protect
ebov
infect
dose
pmo
gave
protect
dose
ppmo
increas
surviv
denvinfect
mice
eight
day
wherea
pmo
provid
surviv
benefit
pmo
could
protect
mice
wnv
infect
ppmo
even
dose
lower
delay
clinic
sign
increas
wnvinfect
mice
surviv
differenti
activ
observ
ebov
studi
may
explain
fact
swenson
et
l
use
rxr
xb
peptid
enterlein
et
al
link
pmo
r
f
c
peptid
peptidenucl
acid
pna
oligonucleotid
analogu
sugarphosph
backbon
replac
peptid
bond
resist
nucleas
proteas
use
antisens
molecul
specif
bind
complementari
dna
rna
sequenc
creat
structur
hindranc
inhibit
viral
transcript
translat
replic
process
report
pna
deliveri
via
cpp
come
pandey
gait
group
work
antivir
target
highlyconserv
regulatori
region
genom
critic
replic
gene
express
primerbind
site
aloop
transactiv
respons
element
tar
studi
author
design
pna
direct
region
inhibit
gene
express
replic
figur
poor
cellular
uptak
uncharg
compound
led
pandey
cowork
coval
conjug
pna
end
variou
cellpenetr
peptid
includ
transportan
tat
penetratin
via
disulfid
bridg
upon
coupl
carrier
peptid
pna
cargo
rapidli
taken
differ
human
cell
type
cultur
ad
cultur
medium
pnacpp
conjug
effect
inhibit
replic
tatdepend
transactiv
viral
product
infect
cell
signific
decreas
observ
unconjug
pna
emphas
great
promis
held
conjug
antivir
agent
turner
et
al
also
chose
enhanc
cellular
deliveri
biolog
activ
pna
coval
attach
cpp
rais
technic
nonetheless
import
question
type
cpp
way
link
pna
affect
abil
pna
reach
cellular
target
conjug
pna
cpp
either
via
stabl
polyeth
linker
cleavabl
disulfid
bond
test
rang
cpp
could
inhibit
tatdepend
transactiv
hela
cell
disulfidelink
conjug
pna
transportan
chimer
peptid
r
penetratin
r
larginin
howev
unlik
report
tripathi
et
l
found
tat
penetratin
conjug
fail
inhibit
transcript
none
conjug
carri
stabl
polyeth
linker
could
elicit
transactiv
inhibit
interestingli
supplement
cell
medium
lysosomotrop
reagent
chloroquin
enhanc
inhibitori
activ
disulfidelink
conjug
stablylink
conjug
gain
inhibitori
activ
support
confoc
microscopi
data
cell
local
conjug
author
argu
endosom
releas
limit
factor
conjug
effici
follow
cell
uptak
cpppna
conjug
would
entrap
endosom
membranebound
cytosol
compart
would
slowli
releas
endosom
entrap
also
report
ppmo
conjug
howev
observ
differ
chaubey
et
al
conclus
conjug
taken
endocyt
pathway
uptak
affect
low
temperatur
phenylarsin
oxid
turner
et
al
attempt
improv
cell
deliveri
also
endosom
releas
properti
cpp
increas
pna
antivir
activ
effect
therapi
current
avail
treatment
jev
infect
yoo
et
al
investig
antivir
activ
exert
variou
pna
direct
jev
rna
cisact
element
pna
conjug
tat
via
olink
promot
effici
cellular
uptak
tatpna
success
inhibit
jev
prolifer
cell
cultur
jev
replic
thought
take
place
special
structur
deriv
host
membran
harbor
viral
rna
polymeras
host
protein
involv
viral
rna
replic
would
mean
tatpna
conjug
cross
plasma
membran
also
abl
penetr
convolut
membran
system
interfer
viral
replic
date
vi
vo
studi
report
cpppna
conjug
field
antivir
pandey
colleagu
start
preliminari
toxic
immunolog
pharmacokinet
studi
mice
pna
tar
penetratin
conjug
chaubey
et
l
report
nontox
complex
administ
repeat
dose
rang
mgkg
mice
given
mgkg
conjug
dose
author
highlight
far
excess
expect
therapeut
dose
suffer
diarrhea
reduc
physic
activ
spleen
liver
kidney
serotosi
howev
recov
followup
period
irrevers
organ
damag
report
upadhyay
et
l
demonstr
pna
tar
penetratin
conjug
moder
immunogen
mainli
due
penetratin
moieti
cytokin
secret
profil
lymph
node
cell
show
elev
level
proinflammatori
cytokin
known
promot
prolifer
lymphocyt
slow
death
cell
author
emphas
immunogen
properti
conjug
could
prove
benefici
host
ganguli
et
l
studi
tissu
distribut
clearanc
ilabel
pna
tar
penetratin
tat
conjug
report
distribut
conjug
throughout
mous
major
intern
organ
administ
oral
rout
well
slow
releas
clearanc
differ
organ
surprisingli
unconjug
nake
pna
tar
display
similar
tissu
distribut
clearanc
profil
although
extent
uptak
lower
cpp
conjug
vi
vo
antivir
activ
pna
tar
penetratin
tat
conjug
need
assess
use
cpp
deliv
sirna
cell
rather
limit
date
even
antivir
sirna
et
al
suggest
sirna
could
less
amen
cpp
deliveri
due
charg
interact
peptid
sirna
ineffici
endosom
escap
conjug
knowledg
report
cppmediat
deliveri
antivir
sirna
meng
et
al
construct
cellperm
sirna
target
hepat
c
viru
untransl
region
sirna
crosslink
end
tat
peptid
author
report
cellular
uptak
antivir
effect
cppsirna
effici
transfect
lipofectamin
cell
cultur
howev
cell
type
refractori
lipofectamin
transfect
moreov
toxic
vivo
cppmediat
deliveri
sirna
definit
worth
investig
cell
type
anim
model
viral
infect
although
kumar
et
al
use
cpp
cell
deliveri
system
per
se
noteworthi
exploit
bind
capabl
polyanion
nucleic
acid
sirna
author
develop
novel
method
system
deliveri
antivir
sirna
cell
mice
use
antibodi
receptor
deliveri
system
receptormedi
endocytosi
bound
sirna
antibodi
posit
charg
nonadarginin
peptid
conjug
ctermin
via
disulfid
bond
success
suppress
infect
human
mous
model
use
cocktail
sirna
complex
inhibit
entri
target
cell
replic
follow
studi
har
carrier
capabl
tat
peptid
shuttl
potenti
antivir
protein
virusinfect
cell
knowledg
first
report
success
use
cpp
deliv
potenti
antivir
agent
cell
voceroakbani
et
al
eleg
studi
author
took
novel
approach
specif
kill
hivinfect
cell
therebi
prevent
product
infecti
virion
engin
zymogen
form
apoptosispromot
enzym
caspas
upon
entri
hivinfect
cell
would
process
activ
form
hiv
proteas
figur
deliv
modifi
jurkat
cell
arm
recombin
protein
tat
peptid
ntermin
author
show
could
transduc
cell
less
min
confoc
analysi
local
fitclabel
cytoplasm
nuclear
compart
remain
inact
uninfect
cell
uptak
result
massiv
apoptosi
hivinfect
jurkat
cell
although
promis
studi
followup
investig
report
due
abil
interact
cellular
viral
protein
protein
st
john
wort
put
forward
potenti
molecul
darbinian
et
l
recent
investig
use
tat
peptid
part
bidirect
protein
transduct
system
antivir
protein
interest
express
tat
ctermin
secret
cell
medium
fusion
protein
effici
enter
hivinfect
cell
tatmedi
uptak
strongli
inhibit
transcript
replic
figur
tat
peptid
also
conjug
peptid
ligand
impair
interact
regulatori
protein
rev
host
cellular
factor
follow
tatmedi
cellular
uptak
primari
lymphocyt
macrophag
inhibitori
heptapeptid
express
fusion
stabil
protein
success
suppress
replic
although
concentr
higher
current
use
antivir
drug
along
better
design
peptid
ligand
conjug
cpp
may
improv
cellular
uptak
therefor
antivir
activ
addit
target
cppmediat
protein
deliveri
exploit
inhibit
human
papillomaviru
type
cell
cultur
mino
et
al
deliv
artifici
zincfing
protein
azp
cultur
cell
express
azp
fusion
peptid
conjug
strongli
inhibit
replic
nm
genedeliv
azp
achiev
inhibit
conjug
also
test
prove
less
effect
azp
fuse
studi
deliveri
antivir
use
peptid
deriv
signal
peptid
bultmann
et
al
found
peptid
exert
antivir
activ
discoveri
led
investig
intrins
antivir
properti
rang
peptid
infect
cultur
cell
test
peptid
includ
eb
stand
entri
blocker
modifi
signal
peptid
tat
kla
synthet
amphipat
peptid
hom
deriv
drosophila
antennapedia
protein
modifi
peptid
particular
tat
peptid
contain
cystein
residu
ctermin
tatc
shown
abl
inhibit
infect
three
way
irrevers
inactiv
virion
expos
tatc
prior
cell
infect
block
entri
celladsorb
virus
induc
state
resist
infect
cell
pretreat
tatc
figur
mechan
antivir
activ
determin
yet
tatc
seem
act
inhibit
viral
entri
fusion
step
rather
viru
attach
step
virion
inactiv
may
result
tatc
bind
sialic
acid
viral
envelop
glycoprotein
along
antivir
properti
pnacpp
complex
chaubey
et
l
tripathi
et
l
investig
virucid
effect
conjug
potenti
use
microbicid
show
preincub
virion
molecul
render
noninfecti
block
cell
infect
two
hypothes
may
explain
result
figur
conjug
may
abl
enter
virion
particl
bind
tar
region
viral
rna
pnacpp
may
also
alter
disrupt
viral
envelop
interact
cpp
moieti
viral
lipid
bilay
therebi
inhibit
host
cell
infect
author
show
brief
exposur
virion
cpppna
conjug
block
endogen
revers
transcript
within
virion
particl
argu
favor
virucid
effect
due
pna
moieti
interact
viral
rna
howev
work
set
stage
explor
activ
display
cpp
cpp
share
structur
similar
membranebind
properti
anoth
class
peptid
antimicrobi
peptid
amp
amp
small
peptid
carri
basic
hydrophob
residu
found
live
organ
mainli
produc
leukocyt
epitheli
cell
major
player
innat
immun
respons
infecti
agent
interestingli
amp
put
forward
one
potenti
class
novel
antivir
antimicrobi
activ
report
envelop
nonenvelop
virus
block
viral
infect
differ
way
directli
inactiv
virion
disrupt
envelop
interact
glycoprotein
act
infect
cell
possibl
interact
cell
receptor
result
alter
cellsign
pathway
requir
viru
replic
block
fusion
viral
membran
endosom
host
cell
therebi
interf
viral
replic
final
interact
inhibit
viral
enzym
essenti
viru
replic
view
similar
cpp
amp
report
effect
peptid
cpp
potenti
intrins
antivir
activ
undoubtedli
deserv
investig
review
studi
contain
common
messag
cppconjug
antivir
agent
hold
great
promis
novel
prevent
therapeut
modal
viral
infect
remark
antivir
effect
ppmo
lethal
infect
ebov
veev
fluav
denv
usuallyleth
infect
wnv
call
wider
use
cpp
deliveri
antivir
drug
cppconjug
antivir
also
show
promis
inhibit
reactiv
latent
infect
virus
moreov
assess
cpp
antivir
properti
understand
molecular
mechan
could
lead
exploit
activ
develop
microbicid
inactiv
virion
exposur
cppantivir
studi
illustr
search
perfect
cppcargo
coupl
cpp
carrier
effici
depend
natur
cargo
affect
antivir
activ
particularli
true
ppmo
research
much
effort
put
toward
develop
highli
activ
peptid
outperform
tradit
use
penetratin
tat
peptid
improv
cpp
endosomolyt
properti
intensifi
antivir
activ
conjug
cargo
becom
main
focu
endosom
escap
appear
critic
antivir
activ
cpp
promot
cellular
uptak
cargo
also
improv
intracellular
traffick
ensur
reach
appropri
cellular
compart
aspect
overlook
design
antivir
differ
virus
may
carri
replic
cycl
differ
subcellular
locat
cytosol
nucleu
intric
membran
system
within
cytosol
type
linkag
cpp
antivir
compound
import
instanc
disulphid
bond
would
result
rapid
releas
cargo
action
cytoplasm
glutathion
therefor
choic
cpp
optim
cargo
also
specif
viru
ensur
antivir
molecul
effici
reach
viral
target
subcellular
compart
research
antivir
cpppna
sirna
protein
conjug
although
encourag
still
infanc
importantli
need
valid
anim
model
need
improv
design
cpp
tackl
issu
vi
vo
toxic
therebi
make
drug
conjug
safer
stein
highlight
even
though
ppmo
dose
regimen
shown
nontox
necessari
show
treatment
dose
sever
time
higher
expect
therapeut
dose
well
toler
noteworthi
ppmo
studi
done
collabor
compani
special
rnabas
drug
avi
biopharma
inc
first
develop
pmo
provid
ppmo
compound
cppantivir
investig
ppmo
studi
one
advanc
stage
sever
report
use
anim
model
direct
wide
rang
virus
work
ppmo
illustr
success
collabor
academia
industri
one
recur
challeng
global
control
viral
infect
develop
drugresist
viral
strain
like
escap
mutant
aris
treatment
especi
longterm
therapi
requir
issu
overcom
treatment
easili
switch
differ
antisens
molecul
eas
synthes
new
cpppna
cppsirna
ppmo
direct
mutat
sequenc
need
address
accord
stein
ppmo
product
costli
complex
investig
limit
vi
vo
studi
potent
ppmo
identifi
cell
cultur
howev
treatment
combin
antisens
molecul
target
multipl
sequenc
viral
genom
greater
antivir
effect
compar
treatment
singl
antisens
molecul
prevent
select
escap
variant
studi
treatment
cocktail
antivir
would
critic
relev
clinic
applic
number
cpp
deriv
viral
protein
tat
fhv
role
cell
penetr
motif
infect
yet
elucid
interest
see
anoth
oblig
intracellular
pathogen
mycobacterium
tuberculosi
also
possess
cell
wall
protein
peptid
sequenc
cpp
repres
exampl
understand
pathogen
interact
human
host
cell
lead
new
way
treat
prevent
viral
infect
